Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT)
Sarah Campbell, Katherine Beaney, Joanne Hosking, Lexy Sorrell, Victoria Allgar, Paigan J Aspinall, Sylwia Ammoun, D Gareth Evans, C O Hanemann, Sarah Kingdon · 2026
Read Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT) by Sarah Campbell, Katherine Beaney, Joanne Hosking, Lexy Sorrell, Victoria Allgar, Paigan J Aspinall, Sylwia Ammoun, D Gareth Evans, C O Hanemann, Sarah Kingdon (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289180.txt.
Description
Sarah Campbell and colleagues lay out a 2026 trial plan on HIV drugs for rare tumors. The RETREAT trial deals with NF2-related growths. No licensed drug treatment exists for this disease. Two HIV drugs slowed such cells in lab tests. Their safety record is already well known.
The trial will enroll up to 16 patients. Treatment will last 30 days. A 30-day follow-up will come next. Skin tumors will be biopsied for study. Blood samples will also be taken. The main check is a drop in tumor signals. Such a drop must be clear in biopsy tissue. The phase 0 design gives a fast read.
Catalog record
| CREATOR | Sarah Campbell, Katherine Beaney, Joanne Hosking, Lexy Sorrell, Victoria Allgar, Paigan J Aspinall, Sylwia Ammoun, D Gareth Evans, C O Hanemann, Sarah Kingdon |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46171 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |